Abbott Launches ILUMIEN IV Trial To Drive Home Case For OCT
ILUMIEN IV is the largest-ever prospective randomized trial to compare an intravascular imaging modality, plus angiography, to angiography alone in coronary interventions, according to Abbott. The trial will enroll up to 3,650 patients with high-risk complex disease at 125 centers in North America, Europe and Asia to determine if OCT-guided stenting yields larger vessel diameters and improves clinical outcomes for patients compared to stent procedures guided by standard angiography.
You may also be interested in...
In an interview with Medtech Insight at this year's JP Morgan Healthcare Conference, the executive VP of medical devices for Abbott Laboratories discussed the firm's recent mega-acquisition of St. Jude Medical, the opportunity in cardiovascular, value-based business models, cybersecurity, and more.
St Jude Medical is to become the first company to offer both optical coherence tomography (OCT) and fractional flow reserve (FFR) technology after agreeing to purchase coronary imaging specialist LightLab Imaging for $90m.
The American Medical Association has written a set of principles for augmented intelligence (AI) development and deployment in health care. The organization hopes these principles can shape “a consistent governance structure for advancements in health care technology.”